Neurosense Therapeutics (NRSN) Regains Nasdaq Compliance

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule") for continued listing.

To regain compliance with the Rule, the Company's ordinary shares were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which was achieved on September 20, 2024. Therefore, the Nasdaq Listing Qualifications Staff considers the prior bid price deficiency matter now closed.

NeuroSense's CEO, Alon Ben-Noon said, " We are pleased to have regained compliance with Nasdaq's minimum bid price requirement, an important step that reflects our commitment to advancing PrimeC. With the positive momentum following our Phase 2b trial results, we are looking forward to initiating the Phase 3 trial in the US and continuing our discussions with potential partners."

You May Also Be Interested In

• Air Canada sells 25% stake in Aeroplan for $2.5 billion
• SEC clears JFB and XTEND merger path ahead of September close
• Aardvark Therapeutics (AARD) Tops Q2 EPS by 21c